262 results
8-K
EX-99.1
GOVX
Geovax Labs Inc
1 Mar 24
GeoVax Reports 2023 Year-End Financial Results
4:09pm
of manufacturing materials for use in our clinical trials, technology license fees, personnel costs, costs of preclinical research activities and higher travel
POS AM
GOVX
Geovax Labs Inc
1 Mar 24
Prospectus update (post-effective amendment)
4:04pm
supplies of our products, our strategy is to rely on established, recognized third-party contract manufacturers to produce materials needed for research … contractors are generally available in the United States and Europe for manufacture of materials for clinical trial evaluation, however, it may be difficult
POS AM
GOVX
Geovax Labs Inc
1 Mar 24
Prospectus update (post-effective amendment)
4:04pm
products, our strategy is to rely on established, recognized third-party contract manufacturers to produce materials needed for research and clinical … are generally available in the United States and Europe for manufacture of materials for clinical trial evaluation, however, it may be difficult to replace
POS AM
f8d7ezm1dxl2n4
1 Mar 24
Prospectus update (post-effective amendment)
4:03pm
POS AM
rbgjols bl
1 Mar 24
Prospectus update (post-effective amendment)
4:03pm
424B3
y6xn7
12 Jan 24
Prospectus supplement
4:00pm
8-K
EX-10.1
l9f vhn8w1shfl
4 Dec 23
Entry into a Material Definitive Agreement
8:00am
8-K
EX-99.1
pbidbqnf6bgeuwqt87p
9 Nov 23
GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update
12:40pm
424B3
ukvciy8gsn p8m
8 Nov 23
Prospectus supplement
4:04pm
424B3
qvs658
8 Nov 23
Prospectus supplement
4:03pm
424B3
xj4kjoxi7cyh
8 Nov 23
Prospectus supplement
4:01pm
8-K
EX-99.1
1j34k w5w04pvjh8qqb
10 Aug 23
GeoVax Reports 2023 Second Quarter Financial Results
9:45am